Clinical trials
RSV Immunization clinical trials
Below are recruiting rsv immunization clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07232706RecruitingPhase 3
RSV prevention in infants with nirsevimab and maternal vaccine
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
La Roche-sur-YonAges 18 years+ - NCT07615192Recruiting
RSV Vaccination Experiences in Queensland Infants
This study asks parents in Queensland about their infant's RSV (respiratory syncytial virus) vaccination status and experiences. RSV is a common virus that can cause serious breathing problems in babies, and this research helps understand vaccination patterns.
Brisbane, QueenslandAges 18 years+ - NCT07734649RecruitingPhase 1/Phase 2
RSV and HMPV vaccine study for adults 60 and older
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
Gadsden, AlabamaAges 60 years+ - NCT07171164Recruiting
Community-based ways to boost RSV vaccine use in Latino adults
This study looks at community-based ways to help Latino adults ages 50 and older in San Francisco and Daly City get the RSV vaccine. The goal is to learn what works best to increase vaccination rates.
San Francisco, CaliforniaAges 18 years+ - NCT07653347Recruiting
Infant RSV immunity study
Researchers want to study how infants naturally fight RSV infections. You and your baby may join if your baby is born in April, May, June, September, October, or November at BC Women's Hospital or a nearby hospital.
Vancouver, British ColumbiaAges Up to 6 months - NCT06180993Recruiting
Nirsevimab for infants born in Galicia
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
Santiago de Compostela, A CoruñaAges 1 day–2 years - NCT07698769Recruiting
Nirsevimab study for infants with RSV bronchiolitis
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
CréteilAges birth–6 months - NCT07203365RecruitingPhase 3
RSV vaccine study for older adults in Sweden
This study tests a vaccine called Arexvy to see if it protects older adults from RSV, a virus that can cause serious lung infections. You must be born between 1965 and 1960 or before 1945, live in Sweden, and be medically stable.
SaltsjöbadenAges 60 years+ - NCT07097012RecruitingPhase 4
Whooping cough and RSV vaccines: together or separate in pregnancy
This study tests whether giving two vaccines—one for whooping cough (Tdap) and one for RSV—at the same time is safe and effective compared to giving them separately during pregnancy. It may help protect your baby from both diseases early in life.
Vancouver, British ColumbiaAges 18–49 - NCT07543380RecruitingPhase 3
RSV vaccine safety and immune response in high-risk adults
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
Tsuchiura, IbarakiAges 18–59 - NCT06401720Enrolling by invitation
Flu immune response study by age
This study looks at how the immune system reacts to the flu in people of different ages. If you have flu symptoms and don't have cancer or take immune-suppressing drugs, you may be able to join.
SödertäljeAges 18 years+ - NCT06998251Recruiting
Immune response to strep pneumonia in older adults
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
GenevaAges 60–85
Hear when a new RSV Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rsv immunization?
- Yes. Clin2 currently lists 12 recruiting rsv immunization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rsv immunization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rsv immunization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.